Pathway enrichment revealed key susceptibilities to developing cardiomyopathies and ischemia due to FGF21 deficiency during fasting, which was potentially mitigated by rhFGF21 treatment (supplementary Fig. 13b and 14c). The gene discussed is FGF21; the disease is cardiomyopathy.